Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

Provided By Globe Newswire

Last update: Jun 16, 2022

Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications